Drug Trial Radar · NCT05567796
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
3,400
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Oct 30, 2024
Study completion Oct 19, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms. Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Conditions
- Obesity
Interventions
CagrilintideDrug
Cagrilintide will be administered subcutaneously.
SemaglutideDrug
Participants will recieve semaglutide subcutaneously.
Placebo cagrilintideDrug
Participants will receive placebo matched to cagrilintide.
Placebo semaglutideDrug
Participants will receive placebo matched to semaglutide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CagriSema versus placebo: Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 68)
- CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reductionTime frame: From baseline (week 0) to end of treatment (week 68)
Locations
256 sites in 23 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Velocity Clin Res Los Angeles
Los Angeles, California
Velocity Clin Res Wstlke
Los Angeles, California
Univ of Colorado at Denver
Aurora, Colorado
OptumCare Clinical Trials LLC
Golden, Colorado
Northeast Research Institute
Fleming Island, Florida
South Broward Research LLC
Miramar, Florida
Clinical Neuroscience Solution
Orlando, Florida
Florida Inst For Clin Res
Orlando, Florida
Florida Institute for Clinical research
Orlando, Florida
Clinical Trial Res Assoc,Inc
Plantation, Florida
Hope Clin Res & Wellness
Conyers, Georgia
East West Med Res Inst
Honolulu, Hawaii
Great Lakes Clinical Trials
Chicago, Illinois
Endeavor Health
Skokie, Illinois
Evanston Premier Hlthcr Res
Skokie, Illinois
Midwest Inst For Clin Res
Indianapolis, Indiana
Northern Pines Hlth Ctr, PC
Buckley, Michigan
StudyMetrix Research LLC
City of Saint Peters, Missouri
Velocity Clinical Research Binghamton
Binghamton, New York
Comprehensive Weight Ctrl Prog
New York, New York
University of North Carolina
Chapel Hill, North Carolina
University of North Carolina
Chapel Hill, North Carolina
Medication Mgmnt, LLC_Grnsboro
Greensboro, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Accellacare_NC
Raleigh, North Carolina
Accellacare
Wilmington, North Carolina
New Venture Medical Research
Wadsworth, Ohio
Lynn Institute of Norman
Norman, Oklahoma
The University of Penn Center
Philadelphia, Pennsylvania
Clinical Res Collaborative
Cumberland, Rhode Island
Medical Uni of SC Charleston
Charleston, South Carolina
Coastal Carolina Res Ctr
North Charleston, South Carolina
Hillcrest Clinical Research
Simpsonville, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
Holston Medical Group_Bristol
Bristol, Tennessee
Holston Medical Group
Kingsport, Tennessee
Baylr Sctt White Rs Inst, Endo
Dallas, Texas
Velocity Clinical Res-Dallas
Dallas, Texas
UT Southwestern Med Cntr
Dallas, Texas
Showing 40 of 256 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.